News – Page 1044 – Endpoints News

GSK tips its hat on new deals, reviews incentives as Hal Barron cooks up a turnaround plan for its lackluster R&D ...

8 years ago

Amid hot IPO season, Mereo drops Nasdaq plans citing 'challenging' market conditions

8 years ago

Celgene's disclosures about ozanimod this week spur analysts' fears of a lengthy delay for a key drug

8 years ago

Roche flags first case of anti-drug antibodies that forced a patient to drop would-be blockbuster Hemlibra

8 years ago

Forget Nasdaq. China’s biotechs with blockbuster IPO dreams are switching focus to Hong Kong

8 years ago

Acadia shares slide — again — after FDA confirms it has launched a safety review of Nuplazid

8 years ago

Venrock-backed startup Corvidia snags $60M round to develop ex-AstraZeneca drug

8 years ago

AbbVie advances its two star pipeline therapies, filing BLA for risankizumab and posting promising data for ...

8 years ago

After mega-round investment, ADC Therapeutics cans PhI trial in HER2

8 years ago

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

8 years ago

After decades in the big leagues, Martin Mackay is going small — and he's delighted

8 years ago

Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff

8 years ago

'Site-less' trials in mind, Novartis launches an app for ophthalmology research

8 years ago

Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

8 years ago

Done deal? Takeda reaches a ‘breakthrough’ in Shire merger talks as deal announcement looms — Reuters

8 years ago

Arrested and charged with fraud, PixarBio CEO Frank Reynolds could face up to 20 years in prison

8 years ago

SCOTUS to biopharma: Inter partes reviews are here to stay, deal with it

8 years ago

Sofinnova leads $32.4 million round for Italy's EryDel; Celgene expands collaboration with Zymeworks

8 years ago

Biotech stars Schleifer and Yancopoulos share $52M in 2017 compensation, even though Regeneron's share price swooned

8 years ago

Shire says Takeda has come up with a new buyout offer as reports spotlight a looming handshake deal

8 years ago

Protein degradation 2.0? Third Rock sinks $56M into Cedilla's unusual approach

8 years ago

Nextech leads a $56M round for the Revolution's move into the clinic

8 years ago

AstraZeneca’s Imfinzi/tremelimumab combo fizzles again on lung cancer

8 years ago

Longtime Sanofi R&D chief Elias Zerhouni is on his way out, handing the research reins to Roche vet John Reed

8 years ago

First page Previous page 1041 1042 104310441045 1046 1047 Next page Last page